BioMarin Pharmaceutical Inc. Q1 FY2026 earnings call

Alexander Hardy mentioned completing the Amicus acquisition, which accelerates 2026 revenue growth. Brian Mueller provided financial updates, noting total revenues, cost of sales, R&D and SG&A expenses. Kristen Hubbard gave commercial updates on enzyme therapies and Voxogo. Greg Freiberg provided R&D updates, including progress on various pipeline programs like Voxogo, BMN401, BMN333, and BMN351

Total revenues in the first quarter were $766 million. Enzyme therapies revenue increased 6% year-over-year, led by growth in Vimizin, Naglizide, and Brynura. Boxergo had strong patient demand with new patient starts increasing across all regions. The acquisition of Amicus accelerates anticipated year-over-year 2026 revenue growth to 20% at the midpoint. Enzyme therapies revenue guidance is raised to a range of $2.725 billion to $2.775 billion for 2026, inclusive of contributions from Gallifold and Pombility and Opfolder. Total revenue guidance is $3.825 billion to $3.925 billion with midpoint representing ~20% year-over-year growth. Boxergo revenue guidance is maintained at $975 million to $1.025 billion. Non-GAAP diluted earnings per share guidance is updated to $4.85 to $5.05

Updated full-year 2026 guidance includes amicus financial outlook. Enzyme therapies revenue guidance raised to $2.725B - $2.775B (30% growth midpoint). Total revenue guidance $3.825B - $3.925B (20% growth midpoint). Boxergo revenue guidance maintained. Non-GAAP diluted EPS guidance $4.85 - $5.05. Acquisition slightly dilutive in 2026, accretive in first 12 months after close and substantially accretive in 2027. More than 55% of 2026 revenues expected in second half. Q2 non-GAAP diluted EPS modestly higher than Q1

Evolving geopolitical uncertainties, especially in the Middle East, which is reflected in the guidance with an allowance for modest disruption. Unsuccessful process qualification campaign for Nagozyme manufacturing capabilities led to a $31M charge in Q1, impacting margins and EPS in the quarter

Q: About recent data at Pediatric Endocrine Society and Voxogo in hypochondriplasia, A: Greg Freiberg discussed the data and expectations.

Q: Regarding integration of Amicus and driving switch rates for Pombility and Opfolder, A: Kristen Hubbard talked about levers for growth.

Q: Early signals of competitor entry on Voxogo, A: Kristen Hubbard provided updates on Q1 performance.

Q: Preview of Amacus integration update next quarter, A: Paul Matisse got responses on revenue outlook, accretion, etc.

Q: Latest on Voxogo in hypochondriplasia and commercial preparations, A: Greg Freiberg and Kristen Hubbard answered.

Q: Guidance increase and contribution from Amicus, A: Brian Mueller provided color.

Q: Adoption of Bugzogo in hypochondriplasia and revenue timing, A: Greg Freiberg and Kristen Hubbard responded.

Q: ITC hearing update and BMN333 trial data, A: Alexander Hardy and Greg Freiberg answered.

Q: Pivotal trial for BMN333 and superiority vs non-inferiority, A: Greg Freiberg and Alexander Hardy responded.

Q: BMA-CC3 and evolving treatment landscape, A: Greg Freiberg responded.

Q: Guidance raise for enzyme therapies and Amicus revenue, A: Brian Mueller reconciled.

Q: ITC manufacturing workaround and POMOP phasing, A: Alexander Hardy and Kristen Hubbard answered